

Date: August 11, 2025

Ref. No.: KDL/SE/040/2025-26

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2025.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Krsnaa Diagnostics Ltd.

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)
020 27402400 | info@krsnaa.in

www.krsnaadiagnostics.com |     

Landmark Rajasthan Project and Strong Earnings Delivery - Cementing Leadership in the Indian PPP Diagnostics Space

Pune, August 11, 2025: Krsnaa Diagnostics Ltd. ([BSE: 543328](#) | [NSE: KRSNAA](#)) is one of India's fastest-growing diagnostic service providers, both in radiology and pathology. The Company today announced the results for the quarter ending June 30th, 2025.

Financial Performance Q1FY2025

Revenue ₹ 1,930 mn 13% YoY ↑

EBITDA ₹ 524 mn 19% YoY ↑

PAT ₹ 205 mn 15% YoY ↑

EPS ₹ 6.3 14% YoY ↑

Financial Overview Q1 FY2026:

(Rs. Million)	Q1FY26	Q1FY25	Y-o-Y Growth	Q4FY25	Q-o-Q Growth	FY25	FY24	Y-o-Y Growth
Revenue from Operations	1,930	1,702	13%	1,861	4%	7,172	6,196	16%
Other Income	40	73		44		255	168	
Total Income	1,970	1,775		1,905		7,427	6,364	
EBITDA ¹	524	442	19%	542	(3%)	1,958	1,466	34%
Margin %	27%	26%		29%		27%	24%	
EBIT ¹	337	285	18%	354	(5%)	1,273	865	47%
Margin %	17%	16%		19%		17%	14%	
Profit After Tax	205	179	15%	207	-	776	568	37%
Margin %	11%	11%		11%		11%	9%	
Reported `Diluted EPS	6.25	5.46		6.28		23.56	17.31	36%

Notes:

1. EBITDA excludes CSR and ESOP and EBIT includes Other Income

Operational Highlights for Q1 FY26:

- Krsnaa has signed the contract to provide pathology services across the state of Rajasthan
- Expanded our presence by establishing 75 new centers across the nation

Commenting on the recent developments & results, **Mr. Yash Mutha, Managing Director**, said:

“We are delighted to share that Krsnaa Diagnostics has been awarded one of the most prestigious and transformative healthcare projects in the state of Rajasthan under the National Health Mission (NHM). After being on hold for some time, this critical project is now set in motion. This landmark initiative will enable us to deliver **best-in-class diagnostic services** to millions of citizens across the state, reinforcing our mission of making quality healthcare accessible to all.

As part of this project, we will establish 42 state-of-the-art Mother Labs, 135 Satellite Labs, and over 1,300 Collection Centers, making it one of the largest and most comprehensive PPP diagnostic projects ever undertaken in India. The scale, reach, and impact of this tender underscore not just the trust placed in Krsnaa Diagnostics but also our proven ability to execute large-scale public health initiatives with excellence.

It marks a defining growth milestone — one that will drive both strategic expansion and long-term value creation while making a meaningful difference in public health delivery.

In Q1FY26, Krsnaa delivered a remarkable 13% year-on-year revenue growth, reaching ₹1,930 million — driven by rising patient trust, growing brand awareness. Krsnaa Diagnostics has delivered breakout retail growth — a 7.9x jump in revenue and a 6.7x surge in touchpoints in just 12 months, now spanning 2,414 locations across four states, we are fast emerging as India's most formidable retail diagnostics growth story. Our services continue to gain traction, with significant increases in test volumes and patient footfall. EBITDA surged 19% YoY to ₹524 million, supported by healthy margin expansion to 27%. Net profit climbed 15% YoY to ₹205 million, with margins improving to 11% — a reflection of our disciplined execution, operational efficiencies, and the strategic rollout of new centers. This consistent performance is a testament to our scalable model, strong governance, and operational agility — qualities that position us to thrive in an evolving and high-growth healthcare ecosystem.

Looking ahead, we are more energized and optimistic than ever. Backed by a seasoned and deeply committed leadership team, we are: 1. Aggressively pursuing high-potential tenders across multiple states. 2. Expanding into new geographies, through both PPP and our fast-growing RPL retail vertical. 3. Strengthening our project pipeline to ensure sustained, predictable growth momentum.

We are also making strategic investments in technology, automation, and digital transformation — unlocking faster turnaround times, seamless patient experiences, and future-ready operations. At Krsnaa Diagnostics, we are building more than a business — we are creating a healthcare movement that empowers communities, strengthens public health infrastructure, and generates long-term value for all stakeholders.”

Commenting on the Business, **Ms. Pallavi Bhatevara, Executive Director**, said:

“At Krsnaa Diagnostics Limited, we remain unwavering in our mission to transform India's diagnostic landscape by making high-quality, affordable, and technology-enabled diagnostic services available to every Indian — regardless of geography, income, or infrastructure barriers.

Diagnostics today are not just a support function in healthcare — they are the bedrock of effective treatment and prevention. With every test we perform, we enable quicker diagnoses, better outcomes, and healthier lives. And we take immense pride in being at the forefront of this transformation — not just participating in the growth of the industry, but leading it.

It is with great pride and optimism that I share a landmark development in our growth journey — the successful execution of the Rajasthan Pathology tender agreement, one of the largest and most strategically significant public healthcare projects in India — this is healthcare infrastructure transformation at population scale. It is a bold demonstration of Krsnaa's unmatched execution capability, speed of deployment, and expertise in navigating complex healthcare ecosystems. With this project, we will touch millions of lives, enabling timely, affordable diagnostics in every corner of Rajasthan. The significance of this win goes far beyond numbers: 1. It cements our leadership position in large-scale Public-Private

Partnerships. 2. It showcases our ability to build state-wide networks with speed, efficiency, and clinical excellence. 3. It further validates the trust governments place in Krsnaa as their implementation partner of choice.

This strategic milestone also significantly strengthens our long-term growth outlook. Our presence across Rajasthan is now comprehensive and deep-rooted, forming a robust platform for further expansion — both in public healthcare and our fast-growing RPL retail brand.

These initiatives are not just about expansion — they are about creating real impact. Whether it's through Public-Private Partnerships (PPP), state healthcare tenders, or direct-to-patient retail offerings under our RPL brand, we have consistently demonstrated our ability to deliver timely, technology-enabled, and patient-centric diagnostic solutions across urban, semi-urban, and rural India.

As we continue to scale and deepen our presence, our core purpose remains unchanged: To be India's most trusted and preferred diagnostics partner — delivering care that is affordable, dependable, and always within reach.

We are excited about what lies ahead. With the Rajasthan project in motion, a strong national pipeline, and growing traction in both PPP and retail, Krsnaa Diagnostics is entering a new phase of accelerated, high-impact growth. And we are confident that we will continue to deliver long-term value to our patients, partners, and investors alike.”

About Krsnaa Diagnostics:

Krsnaa Diagnostics Ltd. is India's fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 15 states and 3 Union Territories with 4,000+ centres across the country. Our mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and our commitment towards the same is what defines and differentiates us. We deliver clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for our patients in any corner of the country. With the most advanced technology in place, equipped with an advanced cloud based PACS workflow capable of rapid deployment and easy integration into flexible operational needs, accurate reports are delivered from well-qualified Radiologists and Pathologists from across the globe. We offer exceptional service with prompt turnaround of diagnostic reports, easy access to consultation with our team of diagnostic specialists, and the ability to handle diagnostic report needs. We provide world class healthcare diagnostics services at affordable rates with the approach of “Let's Do Good...”.

For further information, please contact

Vivek Jain

Head - Investor Relation

[Krsnaa Diagnostics Ltd.](#)

+91 74107 00645

head.investor@krsnaa.in

Safe Harbour

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Krsnaa Diagnostics Ltd and its subsidiaries/ associates (“Krsnaa Diagnostics”). These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Krsnaa Diagnostics, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.